SCHEMBL5772341

SCHEMBL5772341

NS(=O)(=O)CCc1nc(-c2ccc(F)cc2)c(-c2ccc3nnc(-c4ccccc4)n3c2)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.49
MAPK13 O15264 3/20 0.44
GCGR P47871 3/20 0.44
MAPK12 P53778 3/20 0.44
MAPK11 Q15759 3/20 0.44
KDM4E B2RXH2 1/20 0.40
EGFR P00533 3/20 0.37
ALOX5 P09917 3/20 0.36
CYP3A4 P08684 1/20 0.36
GSK3B P49841 1/20 0.35
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA7 P43166 1/20 0.34
CA13 Q8N1Q1 1/20 0.34
SLC2A1 P11166 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5773442 0.77 MAPK14 (0.55) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL5774046 0.74 MAPK14 (0.57) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL5776308 0.73 TGFBR1 (0.58) MAPK14KDM4EGSK3B
SCHEMBL5796403 0.71 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL5775568 0.70 MAPK14 (0.57) MAPK14KDM4EGSK3B
SCHEMBL5775474 0.69 MAPK14 (0.58) MAPK14KDM4E
SCHEMBL5773955 0.69 MAPK14 (0.61) MAPK14KDM4E
SCHEMBL5771177 0.68 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL5775264 0.68 MAPK14 (0.66) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL15007181 0.68 MAPK14 (0.60) MAPK14KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370559-B1 TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS PFIZER PROD INC (US) 2006-04-19 EP disclosed
US-6696464-B2 POTENT INHIBITORS OF MAP KINASES, PREFERABLY P38 KINASE; USEFUL IN TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, REPERFUSION OR ISCHEMIA IN STROKE OR HEART ATTACK PFIZER INC 2004-02-24 US disclosed
EP-1370559-A1 TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS Pfizer Products Inc. (US) 2003-12-17 EP disclosed
US-20030096838-A1 Novel triazolo-pyridines anti-inflammatory compounds PFIZER INC. 2003-05-22 US disclosed
WO-2002072579-A1 TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS PFIZER PRODUCTS INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096838-A1 Novel triazolo-pyridines anti-inflammatory compounds MAPK1, CNKSR1, JAK1 MAPK14 15/4885MAPK13 60/4885GCGR 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.